You are viewing a free limited preview of Auspex Pharmaceuticals, Inc.
For Full Access: Unlock This Company Report For $99 or Upgrade To PrivCo Premium Subscription For Full Site-Wide Access

Auspex Pharmaceuticals, Inc.

Private Company Ticker Symbol™: (AUSPHAP)

Business Summary

Auspex Pharmaceuticals, Inc. is a privately-held, venture capital backed deuteration company. The clinical stage company develops medicines that improve safety and performance. The goal of the company's targeted deuteration strategy is to impart greater safety over existing agents, while maintaining or improving efficacy through the judicious use of deuterium as a replacement for metabolically labile hydrogen atoms. Auspex Pharmaceuticals has applied this targeted deuterations strategy to establish drug molecules across a range of therapeutic areas.. Founded in 2007 by Sepehr Sarshar and Manouchehr Shahbaz, Auspex Pharmaceuticals, Inc. is headquartered in La Jolla, California.

Overview & Corporate Organization

Basic Information

Company Tags:PE Backed
VC Backed
Year Founded:2007
Fiscal Year End:12/31
1YR Revenue Growth Rate:View %
1YR Employee Growth Rate:View %
City:La Jolla
State/Province:California
Country:United States
Phone:View
Fax:View
Website:www.auspexpharma.com

Corporate Organization

Brands:
SD-254
Founders:
Manouchehr Shahbaz
Sepehr Sarshar

Industry Information

Industry Codes

PICS™:1500105™, 1500107
NAICS:View
SIC:View

PrivCo Industries (Sector > Industry > Sub-Industry)

Technology > Biotechnology > Biopharmaceuticals
Technology > Biotechnology > Biotherapeutics

The PrivCo Industry Classification System™ (PICS) is our proprietary, modernized industry classification system, geared especially toward privately-held companies and including newer emerging sub-industries that are not reflected in other outdated industry classification systems, such as SIC and NAICS.

Charts, Financials, and Statistics (Table Format)

Below are Auspex Pharmaceuticals, Inc. financials and other business metrics displayed in table format.
Copy & Paste Financials Into Spreadsheet or Microsoft ExcelExport All Auspex Pharmaceuticals, Inc. Financials To Excel
All data before 2006 is completely free to view! To access data from 2006 onward:
Get Full Access To This Report Now! $99 Single Company Access
 
or Upgrade to PrivCo Premium Subscription Instant Full Site-Wide Access
Currently 50% Off Until May. 31!
Income Statement20112010
RevenuesViewView
Employee Figures20112010
Total EmployeesViewView
Productivity (Revenue/Employee)ViewView
Notes
Financial Notes:
*Auspex Pharmaceuticals, Inc. fiscal year end: 12/31
Microsoft ExcelExport All Auspex Pharmaceuticals, Inc. Financials To Excel

Charts, Financials, and Statistics (Graphs)

Below are Auspex Pharmaceuticals, Inc. financials and other business metrics displayed in table format.
(Copy and paste into spreadsheet or export all Auspex Pharmaceuticals, Inc. financials to Excel and create your own graphs.)
To view the graphs below, unlock this company report for $99 or Upgrade to a PrivCo Premium Subscription for site-wide access to all PrivCo private company research reports.
All data before 2006 is completely free to view! To access data from 2006 onward:
Get Full Access To This Report Now! $99 Single Company Access
 
or Upgrade to PrivCo Premium Subscription Instant Full Site-Wide Access
Currently 50% Off Until May. 31!

Auspex Pharmaceuticals, Inc. Revenues ($):
(Displayed as graph)

Sample Graph
To view the above graph:
Get Full Access To This Report Now! $99 Single Company Access
 
or Upgrade to PrivCo Premium Subscription Instant Full Site-Wide Access
Currently 50% Off Until May. 31!

Auspex Pharmaceuticals, Inc. Total Employees:
(Displayed as graph)

Sample Graph
To view the above graph:
Get Full Access To This Report Now! $99 Single Company Access
 
or Upgrade to PrivCo Premium Subscription Instant Full Site-Wide Access
Currently 50% Off Until May. 31!

Auspex Pharmaceuticals, Inc. Productivity (Revenue/Employee) ($):
(Revenue Per Employee, Displayed as graph)

Sample Graph
To view the above graph:
Get Full Access To This Report Now! $99 Single Company Access
 
or Upgrade to PrivCo Premium Subscription Instant Full Site-Wide Access
Currently 50% Off Until May. 31!
Microsoft ExcelExport Financials to Excel

VC/Funding Activity

PrivCo's VC/Funding Activity table for Auspex Pharmaceuticals, Inc. displays the venture capital rounds, angel investments, debt or other funding raised by Auspex Pharmaceuticals, Inc..
All data before 2006 is completely free to view! To access data from 2006 onward:
Get Full Access To This Report Now! $99 Single Company Access
 
or Upgrade to PrivCo Premium Subscription Instant Full Site-Wide Access
Currently 50% Off Until May. 31!
DateInvestorRoundInvestor Type
May. 2008ViewBPrivate Equity
May. 2008ViewBVenture Capital
DetailsTotal Round B View
Dec. 2008ViewOtherVenture Capital
Dec. 2008ViewOtherVenture Capital
DetailsTotal Round Other View
Aug. 2009ViewDebt FundingVenture Capital
Aug. 2009ViewDebt FundingPrivate Equity
DetailsTotal Round Debt Funding View
Nov. 2009ViewDebt FundingVenture Capital
DetailsTotal Round Debt Funding View
Feb. 2010ViewDebt FundingVenture Capital
DetailsTotal Round Debt Funding1 View
Jul. 2010ViewCVenture Capital
Jul. 2010ViewCPrivate Equity
Jul. 2010ViewCVenture Capital
DetailsTotal Round C View
Dec. 2011ViewDebt FundingVenture Capital
DetailsTotal Round Debt Funding2 View
Nov. 2012ViewDPrivate Equity & Venture Capital
Nov. 2012ViewDPrivate Equity
Nov. 2012ViewDVenture Capital
Nov. 2012ViewDVenture Capital
DetailsTotal Round D View
Mar. 2013ViewDebt FundingOther Investment Firm
DetailsTotal Round Debt Funding View
Total of Funding Shown Above View
Notes
1The issuance included promissory notes...Read More →
2According to an SEC filing...Read More →
Full-length notes are available with Single Report Access or PrivCo Premium Subscription.

Missing a deal? Tell us about it! tips@privco.com

Supplemental Resources

For additional information on Auspex Pharmaceuticals, Inc., you can see the following:

You are viewing a free limited preview of Auspex Pharmaceuticals, Inc.
For Full Access: Unlock This Company Report For $99 or Upgrade To PrivCo Premium Subscription For Full Site-Wide Access